- Copper homeostasis and cuproptosis in central nervous system diseases - Nature
- Newamsterdam's obicetrapib combo nails phase III LDL-C endpoints | BioWorld
- Sage shuts down Huntington's program after phase II failure - BioWorld
- Sage's Pipeline Prospects Narrow Further As Dalzanemdor Fails In Huntington's - Citeline
- RBC upgrades Sage to Sector Perform with negative thesis played out - TipRanks.com
- (PDF) Data-driven Huntington's disease progression modelling and estimation of societal ...
- Cardiovascular Researchers Dramatically Reduce Size and Severity of Stroke Using ... - BioSpace
- Driving Innovation in Aging and Neurodegenerative Research: Henri Ford, MD, MHA
- Synapticure scores $25M to scale platform for neurodegenerative diseases
- Dalzanemdor fails to meet endpoints in phase 2 study of patients with Huntington's disease
- The dust has settled: Sage's dalzanemdor won't advance for cognitive impairment - HDBuzz
- Huntington Agent SAGE-718 to be Discontinued Following Disappointing Phase 2 ... - NeurologyLive
- PhD in Nutrition information session - The Daily | Case Western Reserve University
- Sage's string of research failures continues - Yahoo Finance
- Sage Therapeutics lower as dalzanemdor fails to meet goals - Borsa Italiana
- Facing a Dearth of Big Pharma Interest, Rare Disease Players Get Creative to Fund R&D
- Sage's string of research failures continues | BioPharma Dive
- After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In ...
- Mayo Clinic Studying Use of Neurofilament as Biomarker to Guide Treatment of ALS Patients
- Vivolta, Neurochase team on blood-brain barrier drug delivery system
- Sage to abandon development of neurological disorder drug after multiple failures - Reuters
- Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights
- Sage's dalzanemdor meets its final endpoint after third study failure - FirstWord Pharma
- Updated: Sage reports Phase 2 failure in Huntington's disease, ends drug's development
- Investors tell Silence Therapeutics to shush - STAT News
- Sage Scraps Huntington's Hopeful After Disappointing Phase II Data - BioSpace
- Sage drops dalzanemdor as Huntington's failure completes clean sweep of midphase flops
- Sage Therapeutics scraps development of rare disease drug after it fails mid-stage study
- Sage stock slips as Huntington's Disease trial fails (SAGE:NASDAQ) | Seeking Alpha
- Sage wilts as Huntington's prospect flunks trial - Pharmaphorum
- Sage to abandon development of neurological disorder drug after multiple failures
- DVLA issues update to medical driving licences as Britons risk fines for not reporting conditions
- Sage Therapeutics to end Huntington's disease trial after key therapy fails again
- Sage Therapeutics to end Huntington's disease trial after key therapy fails again
- Sage Therapeutics' stock slides after trial of Huntington's Disease treatment fails and ...
- Sage Therapeutics Ends Huntington's Drug Development After Failed Phase 2 Trial
- Sage Therapeutics : Announces Topline Results from the Phase 2 DIMENSION Study of ...
- Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of ...
- Wave Life Sciences Advances RNA Medicine Innovations - TipRanks.com
- Bryson's Perfect Heart - YouTube
- Dennis Knight - Sanilac County News
- Med's Lindsay Malone offers healthy tips for customizing seasonal coffee drinks
- Synapticure Raises $25M to Expand Virtual Care for Neurodegenerative Diseases
- Meet Dawn Sellers - Bold Journey Magazine
- Med's Xin Qi talks about discovery that could help fight Huntington's disease
- Synapticure Raises $25 Million Series A to Expand Virtual Care for Patients and Caregivers ...
- Dianne M. Avery, 74, of Grafton - Community Advocate
- The Dodgers' World Series run brought attention to a rare disease. Annexon is stepping up ...
- Global Rare Disease Clinical Trials Market Poised for Significant Growth, Projected to ... - WhaTech
- Apathy and Functional Status in Early-Stage Huntington's Disease - Psychiatry Online
